Reno, Nevada 89503


Purpose:

The purpose of the present study is to gather pilot data on the effects of linagliptin on the concentration of the long and short forms of SDF1-α (stromal cell-derived factor alpha) in humans, and to demonstrate the feasibility of such a study in patients with psychosis in our setting.


Study summary:

This study is a 13-week, open-label study of 8 participants with schizophrenia and minimal thought disorder; they will have 12 weeks of treatment and week for assessment. They will receive linagliptin, 5 mg by mouth once per day, while continuing their antipsychotic treatment. The principal outcome measures will be the concentrations of the long and short forms of SDF1-α (stromal cell-derived factor alpha) in blood.


Criteria:

Inclusion Criteria: - Meets DSM (Diagnostic and Statistical Manual) criteria for schizophrenia. - Considered clinically stable, and on the same dose of antipsychotic for two weeks. - A score no greater than 3 on the PANSS (Positive and Negative Syndrome Scale) Conceptual Disorganization item. - Not taking any medications for diabetes, or any anti-inflammatories other than occasional aspirin or acetaminophen. Not taking Clozapine. - Age 18-45 years. - Can be available for regular morning appointments from 8:00 am to 10:00 am, preferably on Tuesdays, Wednesdays and Thursdays. Exclusion Criteria: - Does not meet DSM criteria for substance abuse or dependence. - No serious current general medical condition, such as cancer, history of stroke or myocardial infarction, tuberculosis, HIV/AIDS, hemophilia, etc.


NCT ID:

NCT02442817


Primary Contact:

Principal Investigator
Brian Kirkpatrick, MD
University of Nevada School of Medicine

Brian Kirkpatrick, MD
Phone: 775-682-8449
Email: bkirkpatrick@medicine.nevada.edu


Backup Contact:

Email: agreenhalgh@medicine.nevada.edu
Anne Marie Greenhalgh, BA
Phone: 775-682-8439


Location Contact:

Reno, Nevada 89503
United States

Brian Kirkpatrick, MD
Phone: 775-682-8449
Email: bkirkpatrick@medicine.nevada.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.